Halozyme Therapeutics (DE:RV7)

Halozyme (RV7) Stock Price & Analysis


RV7 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€27.43 - €55.37
Previous Close€37
Average Volume (3M)138.00
Market Cap
Enterprise Value€5.86B
Total Cash (Recent Filing)$483.28M
Total Debt (Recent Filing)$1.50B
Price to Earnings (P/E)N/A
Feb 20, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding132,098,110
10 Day Avg. Volume0
30 Day Avg. Volume138
Standard DeviationN/A
Financial Highlights & Ratios
Price to Book (P/B)-8.02
Price to Sales (P/S)7.38
Price to Cash Flow (P/CF)10.00
P/FCF Ratio9.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.51
Enterprise Value/Gross Profit11.26
Enterprise Value/Ebitda14.42
Price Target Upside29.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9



Ownership Overview

0.00% Mutual Funds
24.21% Other Institutional Investors
75.79% Public Companies and
Individual Investors


What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was €27.43 and its highest was €55.37 in the past 12 months.
    What is Halozyme Therapeutics’s market cap?
    Currently, no data Available
    When is Halozyme Therapeutics’s upcoming earnings report date?
    Halozyme Therapeutics’s upcoming earnings report date is Feb 20, 2024 which is in 72 days.
      How were Halozyme Therapeutics’s earnings last quarter?
      Halozyme Therapeutics released its earnings results on Nov 06, 2023. The company reported €0.695 earnings per share for the quarter, beating the consensus estimate of €0.654 by €0.041.
        Is Halozyme Therapeutics overvalued?
        According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Halozyme Therapeutics pay dividends?
          Halozyme Therapeutics does not currently pay dividends.
          What is Halozyme Therapeutics’s EPS estimate?
          Halozyme Therapeutics’s EPS estimate is €0.71.
            How many shares outstanding does Halozyme Therapeutics have?
            Currently, no data Available
            What happened to Halozyme Therapeutics’s price movement after its last earnings report?
            Halozyme Therapeutics reported an EPS of €0.695 in its last earnings report, beating expectations of €0.654. Following the earnings report the stock price went down -0.879%.
              Which hedge fund is a major shareholder of Halozyme Therapeutics?
              Among the largest hedge funds holding Halozyme Therapeutics’s share is Driehaus Capital Management LLC. It holds Halozyme Therapeutics’s shares valued at 20M.


                Company Description

                Halozyme Therapeutics

                Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Gilead Sciences

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis